Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AnaptysBio has entered into a strategic partnership with Celgene to develop antibodies against multiple therapeutic targets.
Subscribe to our email newsletter
As per the agreement, AnaptysBio will use its SHM-XEL platform to produce therapeutic antibodies to oncology and inflammation-related targets.
Celgene will gain worldwide rights to develop and commercialize antibodies discovered by AnaptysBio.
AnaptysBio is eligible to receive an upfront payment, preclinical and clinical milestone payments from Celgene, as well as royalties upon sales of each product resulting from the partnership.
AnaptysBio president and chief executive officer Hamza Suria said: "We look forward to advancing novel antibody therapeutics with Celgene, in parallel with our internal pipeline programs."